A5014318991- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Global Cancer Incidence and Screening
- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Cervical Cancer and HPV Research
- Multiple and Secondary Primary Cancers
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Myasthenia Gravis and Thymoma
- COVID-19 and healthcare impacts
- Pituitary Gland Disorders and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Global Public Health Policies and Epidemiology
- Gestational Trophoblastic Disease Studies
- Cancer survivorship and care
Instituto Nacional de Enfermedades Neoplásicas
2016-2025
Universidad Peruana Cayetano Heredia
2015-2025
Universidad Científica del Sur
2019-2024
EsSALUD
2018-2024
Universidad Privada San Juan Bautista
2022-2023
Hospital Militar Central
2019
Universidad Ricardo Palma
2019
Universidad de San Martín de Porres
2019
The University of Texas MD Anderson Cancer Center
2019
Massachusetts General Hospital
2016-2017
BackgroundThere are well-known differences in gender outcome non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the influence of patients with NSCLC treated targeted therapy immunotherapy.MethodsWe performed a series meta-analysis compare routine setting for overall survival progression-free (PFS) phase III comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, 6, EURTAC, ENSURE WTJOG); ALK (ASCEND 4,...
Background To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ beyond line, versus matched receiving standard chemotherapy special characterization hyperprogressors. Methods A retrospective cohort study 296 unresectable/metastatic NSCLC treated either, second‐, third‐ fourth‐line was conducted. comparison a historical first‐line and random forest tree analysis to characterize hyperprogressors...
Despite osimertinib being the standard therapy for advanced EGFR T790M mutation positive NSCLC, in many Latin American countries, access to molecular testing and targeted therapies is limited, directly impacting patient outcomes. This study describes real-world management outcomes of Peruvian patients with EGFR-mutated NSCLC who develop mutation. We conducted a multicenter retrospective including from nine institutions, both public private, progressed first-line TKI developed mutation,...
As the fifth international consensus on advanced breast cancer (ABC5) established guidelines for management of this disease, aim article was to present applicability recommendations and generate knowledge improve access.
An in silico pathway analysis was performed an attempt to identify new biomarkers for cervical carcinoma.Three publicly available Affymetrix gene expression data sets (GSE5787, GSE7803, GSE9750) were retrieved, vouching a total 9 cancer cell lines, 39 normal samples, 7 CIN3 samples and 111 samples. Agilent set (GSE7410; 5 35 from invasive cancer) selected as validation set. Predication of microarrays the biomarkers. We compared lists differentially expressed genes between on one hand...
To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in circulating free DNA from a peripheral blood sample before surgery and to determine if this disappears after complete resection tumour.Plasma 10 with was collected preoperative three months surgery. The analysis methylation status promoter SEPT9 performed using 7500 Fast Real-Time PCR System.Hypermethylation detected 8 out samples (one negative result probed be Lynch...
e23308 Background: Epithelial Ovarian Cancer (EOC) is an heterogenous disease which usually diagnosed inadvanced stages. Despite the advent of new therapies, outcomes for this remain poor in certain scenarios. We describe clinical features and survival a developing country. Methods: Retrospective study based on case review women with newly EOC between 2015 2017 at Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima- Peru. Descriptive analysis was conducted characteristics,...
Prostate, breast, colorectal, cervical, and lung cancers are the leading cause of cancer in Latin America Caribbean (LAC) accounting for nearly 50% cases deaths region. Following IARC Code Against Cancer methodology, a group American experts evaluated evidence on several medical interventions to reduce incidence mortality considering burden A recommendation limit use HRT was issued based risk associated develop endometrial, ovarian growing concerns related over-the-counter without...
To determine the clinical and histological characteristics prognostic factors of cervical cancer (CC) in young Peruvian patients.Retrospective analysis patients younger than 35 years old diagnosed with CC between 2008 2012 Instituto Nacional de Enfermedades Neoplásicas.449 had epithelial neoplasms. The main types were: squamous cell carcinoma (84.9%), adenocarcinoma (11.0%) adenosquamous (2.4%). average tumor size was 4.98 cm. Anemia (55.7%), elevated creatinine (21.2%) hydronephrosis...
Background: The COVID-19 pandemic caused discontinuities in cancer care (CC) most countries. Here, the authors describe real-world impacts of implementing a contingency plan employing telemedicine for CC. Methods: A retrospective study patients who received CC through at Instituto Nacional de Enfermedades Neoplasicas, Peru, from March 2020 to February 2021 was conducted. Impacts were measured by comparing amount administered during versus prior year. Results: total 16,456 visits carried out....
The advent of immunotherapy has revolutionized the treatment advanced non-small cell lung cancer (NSCLC), improving prognosis this disease and becoming a key part treatment, especially in population without an oncogenic driver mutation. Two different groups immune checkpoint inhibitors (ICIs) are used cancer: Anti- Cytotoxic T-lymphocyte antigen-4 (Anti-CTLA 4) T-cell receptor programmed death-1 or its ligand (Anti-PD-1 Anti PD-L1). Here in, we review uptodate on use for NSCLC.